These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27222266)

  • 1. Adamantane - A Lead Structure for Drugs in Clinical Practice.
    Spilovska K; Zemek F; Korabecny J; Nepovimova E; Soukup O; Windisch M; Kuca K
    Curr Med Chem; 2016; 23(29):3245-3266. PubMed ID: 27222266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New adamantane derivatives and ways of overcoming the resistance of influenza A viruses to rimantadine and amantadine].
    Shibnev VA; Garayev TM; Finogenova MP; Shevchenko ES; Burtseva EI
    Vopr Virusol; 2011; 56(2):36-9. PubMed ID: 21545040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections.
    Tominack RL; Hayden FG
    Infect Dis Clin North Am; 1987 Jun; 1(2):459-78. PubMed ID: 3332798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Jan; 55(2):44-6. PubMed ID: 16424859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential for the Repurposing of Adamantane Antivirals for COVID-19.
    Butterworth RF
    Drugs R D; 2021 Sep; 21(3):267-272. PubMed ID: 34152583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Croxtall JD; Keam SJ
    Drugs; 2008; 68(16):2387-409. PubMed ID: 18973400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the adamantane structure in medicinal chemistry.
    Lamoureux G; Artavia G
    Curr Med Chem; 2010; 17(26):2967-78. PubMed ID: 20858176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.
    Bull World Health Organ; 1985; 63(1):51-6. PubMed ID: 3872736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes.
    Med Lett Drugs Ther; 2011 Mar; 53(1360):21-2. PubMed ID: 21412207
    [No Abstract]   [Full Text] [Related]  

  • 11. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
    Boulton DW
    Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic effectiveness of bonafton and rimantadine in influenza].
    Krylov VF; Alekseeva AA; Liarskaia TIa; Poliakova TG; Kupriashina LM
    Vopr Virusol; 1976; (2):186-91. PubMed ID: 936578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of natural and synthetic compounds with rigid adamantane-based scaffolds as potential agents for the treatment of neurodegenerative diseases.
    Dembitsky VM; Gloriozova TA; Poroikov VV
    Biochem Biophys Res Commun; 2020 Sep; 529(4):1225-1241. PubMed ID: 32819589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of novel drugs against influenza virus based on synthetic and natural compounds].
    Zarubaev VV; Anfimov PM; Shtro AA; Garshinina AV; Meleshkina IA; Karpinskaia LA; Kozeletskaia KN; Kiselev OI
    Vopr Virusol; 2012; 57(6):30-6. PubMed ID: 23477252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
    He YL; Serra D; Wang Y; Campestrini J; Riviere GJ; Deacon CF; Holst JJ; Schwartz S; Nielsen JC; Ligueros-Saylan M
    Clin Pharmacokinet; 2007; 46(7):577-88. PubMed ID: 17596103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes.
    Ristic S; Bates PC
    Drugs Today (Barc); 2006 Aug; 42(8):519-31. PubMed ID: 16969429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA approves saxagliptin for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2009 Sep; 66(17):1513. PubMed ID: 19710429
    [No Abstract]   [Full Text] [Related]  

  • 19. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
    Lam S; Saad M
    Cardiol Rev; 2010; 18(4):213-7. PubMed ID: 20539105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
    Hu Y; Musharrafieh R; Ma C; Zhang J; Smee DF; DeGrado WF; Wang J
    Antiviral Res; 2017 Apr; 140():45-54. PubMed ID: 28087313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.